Phenothiazine Derivatives: The Importance of Stereoisomerism in the Tolerance and Efficacy of Antimicrobials.
Antimicrobial activity
In vivo models
MRSA
Phenothiazine derivatives
Stereoisomers
Toxicity
Journal
Indian journal of microbiology
ISSN: 0046-8991
Titre abrégé: Indian J Microbiol
Pays: India
ID NLM: 0374703
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
received:
22
03
2023
accepted:
11
05
2024
medline:
16
7
2024
pubmed:
16
7
2024
entrez:
16
7
2024
Statut:
ppublish
Résumé
Stereoisomers are molecules that are identical in atomic constitution and bonding. The biological properties may, however, differ significantly between two enantiomers (individual stereoisomers). JBC 1847, a phenothiazine derivative with strong antimicrobial activity against Gram-positive bacteria, exists in two enantiomers, S and R. Under standard chemical synthesis (S)-and (R)-JBC 1847 will be present in 50/50 amount (racemic). In this study, we have investigated the antimicrobial activity, the in vivo tolerance and therapeutic efficacy of purified (S)-JBC 1847. Compared to JBC 1847 racemic, the antimicrobial activity of (S)-JBC 1847 in vitro was in the same range or slightly increased, while the maximum tolerable concentration in vivo was five times higher for (S)-JBC 1847 (5 mg/kg versus 20 mg/kg bodyweight). Furthermore, the in vivo efficacy of (S)-JBC 1847 in a mouse peritonitis MRSA model was comparable to the activity of vancomycin. In conclusion, the antimicrobial activity and tolerance of a medical stereoisomeric compound may be significantly different using purified enantiomers compared with the racemic state. The online version contains supplementary material available at 10.1007/s12088-024-01309-3.
Identifiants
pubmed: 39010999
doi: 10.1007/s12088-024-01309-3
pii: 1309
pmc: PMC11246383
doi:
Types de publication
Journal Article
Langues
eng
Pagination
743-748Informations de copyright
© The Author(s) 2024.
Déclaration de conflit d'intérêts
Conflict of interestAll authors declare that they have no conflicts of interest.